Latest Period
Q1 2026
Security Snapshot
Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) Institutional Ownership
CUSIP: 055477103
13F Institutional Holders and Ownership History from Q3 2024 to Q1 2026
Institutions Reporting
139
Shares (Excl. Options)
69,711,688
Price
$19.89
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- BCAX on Nasdaq
- Shares outstanding
- 65,361,446
- Price per share
- $21.92
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 69,711,688
- Total reported value
- $1,385,438,188
- % of total 13F portfolios
- 0.01%
- Share change
- +9,367,144
- Value change
- +$187,771,412
- Number of holders
- 139
- Price from insider filings
- $21.92
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- BCAX - Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 055477103.
- 139 institutions reported positions in Q1 2026.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 140 to 139 between Q4 2025 and Q1 2026.
- Reported value moved from $960,809,333 to $1,385,438,188.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 139 institutions filings for Q1 2026.
Investment Quick Answers
What is CUSIP 055477103?
CUSIP 055477103 identifies BCAX - Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 055477103:
Significant Owners of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 12% | $123,100,386 | 7,279,739 | RA Capital Management, L.P. | 26 Feb 2026 | |||
| T. Rowe Price Investment Management, Inc. | 10% | +70% | $131,386,982 | +$67,012,079 | 6,605,780 | +104% | T. Rowe Price Investment Management, Inc. | 31 Mar 2026 |
| Vestal Point Capital, LP | 8.3% | +26% | $120,109,500 | +$40,959,000 | 5,425,000 | +52% | Vestal Point Capital, LP | 31 Mar 2026 |
| Invus Global Management, LLC | 9.6% | $50,656,769 | 5,216,969 | Raymond Debbane | 30 Jun 2025 | |||
| Deep Track Capital, LP | 6.2% | +24% | $89,943,750 | +$29,058,750 | 4,062,500 | +48% | Deep Track Capital, LP | 31 Mar 2026 |
| JANUS HENDERSON GROUP PLC | 5.1% | $73,930,287 | 3,339,218 | JANUS HENDERSON GROUP PLC | 31 Mar 2026 | |||
| Red Tree GP, LLC | 4.8% | $70,195,069 | 3,170,509 | Red Tree GP, LLC | 31 Mar 2026 | |||
| FMR LLC | 3.2% | -48% | $46,514,568 | -$27,592,949 | 2,100,929 | -37% | FMR LLC | 31 Mar 2026 |
As of 31 Mar 2026, 139 institutional investors reported holding 69,711,688 shares of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX). This represents 107% of the company’s total 65,361,446 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) together control 95% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 11% | 7,255,993 | +4.3% | 1.5% | $144,321,701 |
| T. Rowe Price Investment Management, Inc. | 10% | 6,605,780 | +104% | 0.09% | $131,389,000 |
| Siren, L.L.C. | 8.9% | 5,802,970 | +11% | 3.2% | $115,421,073 |
| Vestal Point Capital, LP | 8.3% | 5,425,000 | +52% | 3% | $107,903,250 |
| Deep Track Capital, LP | 6.2% | 4,062,500 | +55% | 1.7% | $80,803,125 |
| JANUS HENDERSON GROUP PLC | 5.1% | 3,326,918 | +26% | 0.03% | $66,105,861 |
| RED TREE MANAGEMENT, LLC | 4.9% | 3,170,509 | 0% | 56% | $63,061,424 |
| TPG GP A, LLC | 4.6% | 3,010,425 | 0% | 1.6% | $59,877,353 |
| BlackRock, Inc. | 4.4% | 2,843,707 | +12% | 0% | $56,561,328 |
| Omega Fund Management, LLC | 3.7% | 2,392,150 | +8.5% | 29% | $47,579,864 |
| Royalty Pharma Sub-Manager, LLC | 3.7% | 2,388,150 | 0% | 27% | $46,688,333 |
| FMR LLC | 3.2% | 2,100,929 | -37% | 0% | $41,787,477 |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.7% | 1,774,220 | 0% | 0% | $35,289,236 |
| CITADEL ADVISORS LLC | 2.5% | 1,659,342 | +115% | 0.02% | $33,004,313 |
| FRANKLIN RESOURCES INC | 2.5% | 1,621,643 | +0.1% | 0.01% | $32,254,484 |
| STATE STREET CORP | 2.2% | 1,419,388 | -14% | 0% | $28,231,627 |
| PRICE T ROWE ASSOCIATES INC /MD/ | 2.1% | 1,376,198 | -12% | 0% | $27,374,000 |
| Jones Hill Capital LP | 1.9% | 1,260,136 | 0% | 5.4% | $25,064,105 |
| GEODE CAPITAL MANAGEMENT, LLC | 1.3% | 830,906 | +2.4% | 0% | $16,530,951 |
| FIL Ltd | 1% | 679,904 | -10% | 0.01% | $13,523,291 |
| ORBIMED ADVISORS LLC | 1% | 667,300 | +219% | 0.3% | $13,272,597 |
| ACORN CAPITAL ADVISORS, LLC | 0.98% | 643,382 | 0% | 3.6% | $12,796,860 |
| Aisling Capital Management LP | 0.87% | 568,919 | 0% | 2.4% | $11,315,799 |
| GOLDMAN SACHS GROUP INC | 0.86% | 558,964 | +1.2% | 0% | $11,117,794 |
| Palo Alto Investors LP | 0.84% | 550,408 | +84% | 1.7% | $10,947,615 |
Institutional Holders of Bicara Therapeutics Inc. - Common Stock, par value $0.0001 per share (BCAX) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 69,711,688 | $1,385,438,188 | +$187,771,412 | $19.89 | 139 |
| 2025 Q4 | 57,096,017 | $960,809,333 | +$119,906,754 | $16.83 | 140 |
| 2025 Q3 | 49,994,786 | $789,088,187 | +$2,780,392 | $15.79 | 112 |
| 2025 Q2 | 51,165,684 | $475,330,436 | -$6,689,372 | $9.29 | 105 |
| 2025 Q1 | 48,567,553 | $633,357,650 | +$9,523,679 | $13.03 | 92 |
| 2024 Q4 | 46,709,070 | $813,618,424 | +$73,899,338 | $17.42 | 84 |
| 2024 Q3 | 36,408,664 | $927,393,381 | +$849,110,088 | $25.47 | 69 |